PP
CYCN icon

PDT Partners’s Cyclerion Therapeutics CYCN Stock Holding History

PDT Partners’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,505
Closed -$92K – 896
2021
Q3 		$92K Sell
1,505
-640
-30% -$41.9K 0.01% 736
2021
Q2 		$167K Hold
2,145
– – 0.01% 727
2021
Q1 		$120K Buy
2,145
+915
+74% +$68.7K 0.01% 731
2020
Q4 		$75K Hold
1,230
– – 0.01% 665
2020
Q3 		$150K Buy
1,230
+367
+43% +$42K 0.01% 659
2020
Q2 		$102K Sell
863
-870
-50% -$72.7K 0.01% 631
2020
Q1 		$92K Buy
+1,733
New +$124K 0.01% 617

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PDT Partners's CYCN Position: Q4 2021 in Review

PDT Partners sold out of Cyclerion Therapeutics (CYCN) in Q4 2021, closing a stake of 1,505 shares — an estimated $92K sold.

PDT Partners first reported a position in CYCN in Q1 2020 and held it in 7 quarters. The position peaked at $167K in Q2 2021. 56 funds tracked by Wall St. Rank hold CYCN as of Q4 2021.

  • PDT Partners reported no remaining Cyclerion Therapeutics position as of Q4 2021 after selling out during the quarter.
  • PDT Partners sold 1,505 Cyclerion Therapeutics shares in Q4 2021, an estimated $92K.
  • PDT Partners first reported a position in Cyclerion Therapeutics in Q1 2020 and held it in 7 quarters.
  • PDT Partners's Cyclerion Therapeutics position peaked at $167K in Q2 2021.
  • 56 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2021.

Based on PDT Partners's 13F filing for Q4 2021, filed 14 Feb 2022.